Literature DB >> 16998679

Long-term outcome after resection of non-small cell lung carcinoma complicated by pneumoconiosis.

Yuma Ebihara1, Yutaka Makino, Masaki Miyamoto, Masahito Hashimoto, Satoshi Kondo.   

Abstract

PURPOSE: Lung cancer resection in patients with respiratory complications is associated with a high surgical risk and the operative indications are usually serious. Consequently, the long-term results are unclear. We aimed to clarify the validity of surgery for non-small cell lung cancer (NSCLC) in patients with pneumoconiosis.
METHODS: We reviewed the clinical and pathological data of 122 patients undergoing resection of NSCLC with pneumoconiosis (n = 34: group A) or without pneumoconiosis (n = 88: group B) to assess treatment outcomes and prognostic factors.
RESULTS: Among the treatment factors, intraoperative blood loss was significantly greater in group A (723.2 +/- 647.3 ml) than in group B (466.4 +/- 450.7 ml) (P = 0.0067), although the operative times (207 +/- 103.4 min vs 196.1 +/- 53.5 min, respectively) and postoperative drainage period (8.3 +/- 4.2 days vs 8.5 +/- 5.7 days, respectively) did not differ significantly between the two groups (P = 0.9466 and P = 0.6355, respectively). Among the postoperative complications, the incidence of hemorrhage was significantly higher in group A (29.4%) than in group B (7.9%) (P = 0.0022). The 5-year survival rates did not differ significantly between the two groups, (45.9% and 55.7% for groups A and B respectively) (P = 0.9424).
CONCLUSIONS: The coexistence of pneumoconiosis does not adversely affect postoperative survival or the treatment of NSCLC, although it is associated with increased intraoperative blood loss and postoperative hemorrhage. Thus, if precautions are taken to minimize hemorrhage, surgery cannot be excluded as a treatment option for NSCLC in patients with pneumoconiosis.

Entities:  

Mesh:

Year:  2006        PMID: 16998679     DOI: 10.1007/s00595-006-3264-z

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  10 in total

1.  [Clinical study of lung cancer complicated by pneumoconiosis].

Authors:  Y Kojima
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  1998-09

2.  Non-randomized controls in cancer clinical trials.

Authors:  E A Gehan; E J Freireich
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

3.  Carcinoma of the lung and anthracosilicosis.

Authors:  D Scarano; A M Fadali; G M Lemole
Journal:  Chest       Date:  1972-09       Impact factor: 9.410

4.  Pneumoconiosis-related lung cancers: preferential occurrence from diffuse interstitial fibrosis-type pneumoconiosis.

Authors:  M Katabami; H Dosaka-Akita; K Honma; Y Saitoh; K Kimura; Y Uchida; H Mikami; Y Ohsaki; Y Kawakami; K Kikuchi
Journal:  Am J Respir Crit Care Med       Date:  2000-07       Impact factor: 21.405

Review 5.  Ulcerative colitis and colon cancer.

Authors:  G Isbell; B Levin
Journal:  Gastroenterol Clin North Am       Date:  1988-12       Impact factor: 3.806

6.  k-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis.

Authors:  H H Nelson; D C Christiani; J K Wiencke; E J Mark; J C Wain; K T Kelsey
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

7.  Silicosis, mixed dust pneumoconiosis, and lung cancer.

Authors:  K Honma; K Chiyotani; K Kimura
Journal:  Am J Ind Med       Date:  1997-12       Impact factor: 2.214

8.  Thoracic surgical problems in asbestos-related disorders.

Authors:  E A Gaensler; T C McLoud; C B Carrington
Journal:  Ann Thorac Surg       Date:  1985-07       Impact factor: 4.330

9.  Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis.

Authors:  R Shimoda; M Nagashima; M Sakamoto; N Yamaguchi; S Hirohashi; J Yokota; H Kasai
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

10.  Cryptogenic fibrosing alveolitis and lung cancer.

Authors:  M Turner-Warwick; M Lebowitz; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-07       Impact factor: 9.139

  10 in total
  1 in total

1.  LigaSure meets endobronchial valve in a case of lung cancer with pneumoconiosis.

Authors:  Alfonso Fiorelli; Marina Accardo; Giovanni Vicidomini; Mario Santini
Journal:  Transl Lung Cancer Res       Date:  2013-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.